--- title: "Lantheus | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 388.18 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295102360.md" datetime: "2026-08-06T11:46:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295102360.md) - [en](https://longbridge.com/en/news/295102360.md) - [zh-HK](https://longbridge.com/zh-HK/news/295102360.md) --- # Lantheus | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 388.18 M Revenue: As of FY2026 Q2, the actual value is USD 388.18 M, beating the estimate of USD 363.23 M. EPS: As of FY2026 Q2, the actual value is USD 1.11, beating the estimate of USD 0.89. EBIT: As of FY2026 Q2, the actual value is USD 98.74 M. The provided 8-K filing by Lantheus Holdings, Inc. indicates that the company announced its financial results for the three and six months ended June 30, 2026, via a press release on August 6, 2026, but the 8-K filing itself does not contain specific financial or operational metrics. All following metrics are derived from the furnished press release. #### Worldwide Revenue Worldwide revenue increased 2.7% to $388.2 million compared to the same period in 2025. #### Net Income GAAP net income was $75.0 million, a decrease of 4.7% compared to $78.8 million in Q2 2025. Adjusted net income (non-GAAP) was $104.9 million, a decrease of 5.1% compared to $110.6 million in Q2 2025. #### Operating Income Operating income increased 13.9% to $100.2 million. Adjusted operating income (non-GAAP) decreased 6.9% to $142.0 million. #### Gross Profit Gross profit was $241,855 thousand, compared to $241,011 thousand in Q2 2025. #### Operating Expenses - Sales and marketing expenses were $82,805 thousand, compared to $41,041 thousand in Q2 2025. - General and administrative expenses were $20,633 thousand, compared to $66,515 thousand in Q2 2025. - Research and development expenses were $38,202 thousand, compared to $45,489 thousand in Q2 2025. - Total operating expenses were $141,640 thousand, compared to $153,045 thousand in Q2 2025. #### Segment Revenue - Sales of PYLARIFY were $240.4 million, a decrease of 4.1%. - Sales of Neuraceq were $39.6 million. - Sales of DEFINITY were $88.3 million, an increase of 5.2%. - Total oncology revenue was $240,366 thousand, a -4.1% change from $250,642 thousand in Q2 2025. - Total neurology revenue was $39,616 thousand, a 100.0% change from Q2 2025. - Total cardiology revenue was $88,279 thousand, a 5.2% change from $83,939 thousand in Q2 2025. - Strategic partnerships and other revenue was $19,919 thousand, a 71.9% change from $11,590 thousand in Q2 2025. - SPECT revenue was $0, a -100.0% change from $31,874 thousand in Q2 2025. #### Cash Flow Net cash provided by operating activities was $92.2 million. Free cash flow was $89.9 million. Capital expenditures were - $2,335 thousand. Net cash used in investing activities was - $2,023 thousand. Net cash provided by financing activities was $4,505 thousand. #### Balance Sheet Highlights (as of June 30, 2026) Cash and cash equivalents were $593.3 million, compared to $359.1 million at December 31, 2025. The company has access to up to $750.0 million from a revolving line of credit. #### Outlook / Guidance Lantheus Holdings, Inc. is suspending its previously issued full year 2026 financial guidance due to a pending transaction. The company will not be hosting a conference call in connection with its second quarter 2026 results. #### Merger Announcement On August 3, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to merge with Curium, under which Curium US Holdings LLC will acquire all outstanding shares. The transaction involves $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights providing up to $12.00 per share in potential additional cash payments, for a total transaction value of up to approximately $8.0 billion. Lantheus Holdings, Inc.’s Board of Directors unanimously approved the transaction. ### Related Stocks - [LNTH.US](https://longbridge.com/en/quote/LNTH.US.md) ## Related News & Research - [Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS](https://longbridge.com/en/news/295287832.md) - [Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH](https://longbridge.com/en/news/295252919.md) - [Lantheus Q2 revenue rises 2.7%, beats estimates](https://longbridge.com/en/news/295097525.md) - [Berkshire Hathaway Just Gave Investors a Clue About When to Buy the Stock](https://longbridge.com/en/news/295679944.md) - [Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/295266023.md)